RxDoctor Payments Data

Haley Lowell

Family Medicine · Ottawa, KSNPI 1619461183

Payments from drug & device makers

$378in general payments, 2019–2025

Across 24 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$66
  • Pfizer$55
  • AstraZeneca$43
  • Sanofi-aventis U.S. LLC$28
  • Boston Scientific$28
  • Grifols USA, LLC$22
  • plus $135 from 9 others

What the payments were for

  • Food & beverage$378100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$378 in reported general payments places this provider in the 45th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$15,212
Medicare patients
62
Services billed
171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide75$78,893
FarxigaDapagliflozin Propanediol77$57,184
EliquisApixaban74$43,921
RybelsusSemaglutide22$27,234
JardianceEmpagliflozin42$20,609
OzempicSemaglutide15$15,656
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,596
InvokanaCanagliflozin12$7,389
JanuviaSitagliptin Phosphate12$7,075
XareltoRivaroxaban14$5,060
EntrestoSacubitril/Valsartan27$4,671
MyrbetriqMirabegron19$4,376
Midodrine Hcl44$4,027
LumiganBimatoprost13$3,559
Levothyroxine Sodium386$3,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$43$57,18477 claims
PfizerEliquis$55$43,92174 claims
Novo NordiskRybelsus, Ozempic$66$42,89137 claims
MerckJanuvia$14$7,07512 claims
NovartisEntresto$15$4,67127 claims
AbbVieLumigan$20$3,55913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Ottawa

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →